Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Niederkofler, Eric E ^a   Phillips, David A ^a   Krastins, Bryan ^a   Kulasingam, Vathany ^b   Kiernan, Urban A ^a   Tubbs, Kemmons A ^a   Peterman, Scott M ^a   Prakash, Amol ^a   Diamandis, Eleftherios P ^b   Lopez, Mary F ^a   Nedelkov, Dobrin ^a  

^a Thermo Fisher Scientific   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; SOMATOMEDIN C; TRYPSIN; BIOLOGICAL MARKER;

ANTIBODY AFFINITY; ARTICLE; BLOOD SAMPLING; ELUTION; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MONITORING; QUANTITATIVE ANALYSIS; SEPARATION TECHNIQUE; STANDARD; BLOOD; CHEMISTRY; METABOLISM; PROCEDURES; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS;

BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; INSULIN-LIKE GROWTH FACTOR I; MASS SPECTROMETRY; REFERENCE STANDARDS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84896736495     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081125     Document Type: Article

References (37)

1. Zapf J, Froesch ER, Schmid C (1999) Metabolic effects of IGFs. In: Conn M, editor. Contemporary Endocrinology17: the IGF system - molecular biology, physiology and clinical applications. New Jersey: Humana Press.
2. Forbes BE, McCarthy P, Norton RS (2012) Insulin-like growth factor binding proteins: a structural perspective. Front Endocrinol (Lausanne) 3: 38.
3. Clemmons DR (2007) IGF-I assays: current assay methodologies and their limitations. Pituitary 10: 121-128.
4. Frystyk J, Freda P, Clemmons DR (2010) The current status of IGF-I assays - a 2009 update. Growth Horm IGF Res 20: 8-18.
5. Bobin S, Popot MA, Bonnaire Y, Tabet JC (2001) Approach to the determination of insulin-like-growth-factor-I (IGF-I) concentration in plasma by high-performance liquid chromatography-ion trap mass spectrometry: use of a deconvolution algorithm for the quantification of multiprotonated molecules in electrospray ionization. Analyst 126: 1996-2001.
6. de Kock SS, Rodgers JP, Swanepoel BC (2001) Growth hormone abuse in the horse: preliminary assessment of a mass spectrometric procedure for IGF-1 identification and quantitation. Rapid Commun Mass Spectrom 15: 1191-1197.
7. Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA (2004) Quantitative mass spectrometric immunoasay of insulin like growth factor 1. J Proteome Res 3: 851-855.
8. Kirsch S, Widart J, Louette J, Focant JF, De Pauw E (2007) Development of an absolute quantification method targeting growth hormone biomarkers using liquid chromatography coupled to isotope dilution mass spectrometry. J Chromatogr A 1153: 300-306.
9. Bredehoft M, Schanzer W, Thevis M (2008) Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 22: 477-485.
10. Kay RG, Barton C, Velloso CP, Brown PR, Bartlett C, et al. (2009) High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Commun Mass Spectrom 23: 3173-3182.
11. Barton C, Kay RG, Gentzer W, Vitzthum F, Pleasance S (2010) Development of high-throughput chemical extraction techniques and quantitative HPLC-MS/MS (SRM) assays for clinically relevant plasma proteins. J Proteome Res 9: 333-340.
12. Bystrom C, Sheng S, Zhang K, Caulfield M, Clarke NJ, et al. (2012) Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry. PLoS One 7: e43457.
13. Bystrom CE, Sheng S, Clarke NJ (2011) Narrow mass extraction of time-of-flight data for quantitative analysis of proteins: determination of insulin-like growth factor-1. Anal Chem 83: 9005-9010.
14. Kay R, Halsall DJ, Annamalai AK, Kandasamy N, Taylor K, et al. (2013) A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly. Clin Endocrinol (Oxf) 78: 424-430.
15. Thomas A, Kohler M, Schanzer W, Delahaut P, Thevis M (2011) Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. Analyst 136: 1003-1012.
16. Bang P, Eriksson U, Sara V, Wivall IL, Hall K (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 124: 620-629.
17. Breier BH, Gallaher BW, Gluckman PD (1991) Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J Endocrinol 128: 347-357.
18. Daughaday WH, Mariz IK, Blethen SL (1980) Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab 51: 781-788.
19. Lopez MF, Rezai T, Sarracino DA, Prakash A, Krastins B, et al. (2010) Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 56: 281-290.
20. Nedelkov D (2012) Mass spectrometry-based protein assays for in vitro diagnostic testing. Expert Rev Mol Diagn 12: 235-239.
21. Trenchevska O, Kamcheva E, Nedelkov D (2010) Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J Proteome Res 9: 5969-5973.
22. Lange V, Picotti P, Domon B, Aebersold R (2008) Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 4: 222.
23. Kuhn E, Whiteaker JR, Mani DR, Jackson AM, Zhao L, et al. (2012) Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics 11: M111 013854.
24. Whiteaker JR, Zhao L, Abbatiello SE, Burgess M, Kuhn E, et al. (2011) Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics 10: M110 005645.
25. Brun V, Dupuis A, Adrait A, Marcellin M, Thomas D, et al. (2007) Isotope-labeled protein standards: toward absolute quantitative proteomics. Mol Cell Proteomics 6: 2139-2149.
26. Niederkofler EE, Tubbs KA, Gruber K, Nedelkov D, Kiernan UA, et al. (2001) Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal Chem 73: 3294-3299.
27. Tubbs KA, Nedelkov D, Nelson RW (2001) Detection and quantification of beta-2-microglobulin using mass spectrometric immunoassay. Anal Biochem 289: 26-35.
28. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, et al. (2009) Multisite assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27: 633-641.
29. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, et al. (2008) Detection of Endogenous B-Type Natriuretic Peptide at Very Low Concentrations in Patients With Heart Failure. Circulation: Heart Failure November 1: 258-264.
30. Soldin OP, Dahlin JR, Gresham EG, King J, Soldin SJ (2008) IMMULITE 2000 age and sex-specific reference intervals for alpha fetoprotein, homocysteine, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein-3, C-peptide, immunoglobulin E and intact parathyroid hormone. Clin Biochem 41: 937-942.
31. Passing H, Bablok(1983) A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 21: 709-720.
32. Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods Med Res 8: 135-160.
33. Krebs A, Wallaschofski H, Spilcke-Liss E, Kohlmann T, Brabant G, et al. (2008) Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clin Chem Lab Med 46: 1776-1783.
34. Burns C, Rigsby P, Moore M, Rafferty B (2009) The First International Standard For Insulin-like Growth Factor-1 (IGF-1) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res 19: 457-462.
35. Cox HD, Rampton J, Eichner D (2013) Quantification of insulin-like growth factor-1 in dried blood spots for detection of growth hormone abuse in sport. Anal Bioanal Chem 405: 1949-1958.
36. Prakash A, Rezai T, Krastins B, Sarracino D, Athanas M, et al. (2012) Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J Proteome Res 11: 3986-3995.
37. Brugts MP, Luermans JG, Lentjes EG, van Trooyen-van Vrouwerff NJ, van der Horst FA, et al. (2009) Heterophilic antibodies may be a cause of falsely low total IGF1 levels. Eur J Endocrinol 161: 561-565.